SAGE Therapeutics (SAGE) Misses Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Oppenheimer Reiterates Perform Rating on Sage Therapeutics (SAGE)
August 7, 2023 4:56 PM EDTOppenheimer analyst Jay Olson reiterated a Perform rating and $20.00 price target on Sage Therapeutics (NASDAQ: SAGE)
The analyst comments "SAGE is focused on delivering newly-approved Zurzuvae to PPD patients while accelerating development of pipeline assets and rationalizing OpEx spending. We... More
SAGE Therapeutics (SAGE) sinks nearly 50% as trading resumes following CRL
August 7, 2023 7:12 AM EDTSAGE Therapeutics (NASDAQ: SAGE) sinks 47% as trading resumes after FDA approval for ZURZUVAETM in postpartum depression (PPD) but a CRL for major depressive disorder (MDD).
... More